• Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic

  NCT03942848

  Unknown statusInterventionalPhase 3Updated May 8, 2019
• Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

  NCT00076544

  CompletedInterventionalPhase 3Updated Dec 14, 2015
• Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

  NCT07499882

  Not yet recruitingObservationalUpdated Mar 30, 2026
• Ziconotide as First-Line IDT

  NCT03321955

  CompletedInterventionalPhase 4Updated Jan 12, 2021
• Prialt (Ziconotide) In Severe Chronic Pain

  NCT00047749

  CompletedInterventionalPhase 3Updated Dec 14, 2015
• Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

  NCT00996983

  Unknown statusInterventionalPhase 2Updated Mar 24, 2023

ClinicalTrials.gov ID

NCT06541184

Lead Sponsor

ESTEVE Pharmaceuticals SASINDUSTRY

Overall Status

Recruiting

Study Type

Observational

Enrollment

85Estimated

Last Update Posted

Feb 27, 2025Actual

Start Date

Oct 30, 2024Actual

Primary Completion Date

Oct 30, 2029Estimated

Completion Date

Oct 30, 2029Estimated

Official Title

Ziconotide for Non-cancer Pain by Intrathecal Administration

Brief Summary

Although ziconotide's marketing authorization does not restrict its use to a given type of pain, the drug has been used mainly in cancer patients. Most data on ziconotide-based intrathecal (IT) treatment has therefore been obtained in this population, for whom the drug's place is clearly documented (national and international recommendations).

In contrast the management of non-cancer pain is less straightforward, partly because of the very large range of possible clinical conditions, and the utilization of ziconotide is poorly documented, mainly described in single-centre small series.

Due to the lack of data, physicians are often reluctant to undertake this type of treatment, which may represent a loss of opportunity for patients.

This registry aims at providing information on patients suffering from non-cancer pain refractory to standard therapy, treated by ziconotide-based intrathecal analgesia.

Patients suffering from all types of non-malignant pain will be eligible for the study, including but not limited to spinal cord injury, radiculopathy, failed back surgery, diabetic neuropathy, central pain syndrome, complex regional pain syndrome, chemotherapy-induced neuropathy, fibromyalgia.

The collected data will cover the first 2 years of treatment.

• Pain, Chronic

• Ziconotide [Prialt]

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age ≥18 years,
2. Chronic non-cancer pain requiring interventional techniques, and eligible to ziconotide-containing intrathecal therapy,
3. Having received information on and not opposed to data collection,

Inclusion criteria specific for the retrospective cohort:

Currently treated by ziconotide-based ITA according to SmPC whatever the duration of treatment

Inclusion criteria specific for the prospective cohort:

Naïve of ITA and candidate to ziconotide-based ITA or already treated by IT route without ziconotide, scheduled for addition of ziconotide in the pump

Exclusion Criteria:

1. Contraindication to intrathecal therapy or to ziconotide
2. Any condition that may jeopardize appropriate follow-up of the treatment
3. Patient under guardianship or deprived of liberty by a judicial or administrative decision or unable to express opposition to data collection.

Observational Model

Case-Only

Time Perspective

Other

Lead Sponsor

ESTEVE Pharmaceuticals SASINDUSTRY

jean-marie.leborgne@ch-laon.fr

gilles.lebuffe@chu-lille.fr

bmarlier@chu-reims.fr